Oct 29 (Reuters) - Industrial equipment maker IDEX Corp ( IEX )

on Wednesday posted a stronger-than-expected profit and

revenue for the third quarter, helped by a protracted recovery

in its health and science product lines.

Sales in the health and science technology segment rose 22%

from a year earlier, as customers continued to restock after

working through the large inventories built up during the

COVID-19 pandemic.

The unit supplies components used in clinical diagnostics

and drug discovery, as well as in food processing and cosmetic

manufacturing.

IDEX ( IEX ) narrowed its 2025 adjusted profit to between $7.86 and

$7.91, compared with a prior view of $7.85 to $7.95.

Excluding items, the company's quarterly earnings stood at

$2.03 per share, higher than Wall Street expectations of $1.93,

according to data compiled by LSEG.

Its total revenue rose 10% to nearly $879 million for the

quarter ended September 30, while analysts on average were

expecting revenue of $862 million.